{"id":35162,"date":"2013-03-10T12:12:03","date_gmt":"2013-03-10T16:12:03","guid":{"rendered":"http:\/\/blogs.nejm.org\/cardioexchange\/?post_type=news&p=35162"},"modified":"2013-03-10T12:18:37","modified_gmt":"2013-03-10T16:18:37","slug":"cangrelor-during-pci-may-reduce-ischemic-events","status":"publish","type":"post","link":"https:\/\/blogs.nejm.org\/cardioexchange\/2013\/03\/10\/cangrelor-during-pci-may-reduce-ischemic-events\/","title":{"rendered":"Cangrelor During PCI May Reduce Ischemic Events"},"content":{"rendered":"

For more of our ACC.13 coverage of late-breaking clinical trials, interviews with the authors of the most important research, and blogs from our fellows on the most interesting presentations at the meeting, check out our Coverage Headquarters<\/strong><\/a>.<\/em><\/p>\n

In the Cangrelor versus Standard Therapy to Achieve Optimal Management of Platelet Inhibition (CHAMPION PHOENIX) trial, the intravenous platelet inhibitor cangrelor was tested for its effect on ischemic events associated with PCI. Cangrelor is a potent, fast-acting and reversible \u00a0agent. Results of the trial were presented at the ACC in San Francisco and published simultaneously in the\u00a0New England Journal of Medicine<\/em><\/a>.<\/p>\n

A total of 11,145 PCI patients were randomized to a bolus and infusion of cangrelor or to a loading dose of clopidogrel.\u00a0A primary endpoint event — death, MI, ischemia-driven revascularization, or stent thrombosis at 48 hours — occurred in 4.7% of the cangrelor group versus 5.9% of the clopidogrel group (adjusted OR, 0.78; 95% CI, 0.66-0.93; P<\/em>=0.005). The authors calculated that 84 patients would need to be treated with cangrelor instead of clopidogrel to prevent one primary endpoint event.<\/p>\n

Cangrelor treatment was not associated with an increased risk for bleeding but was associated with a significant reduction in stent thrombosis:<\/p>\n